Evaluating Gefitinib, Erlotinib, and Cetuximab Efficacy

Cells were seeded at a density of 10,000 cells/well in a 96-well plate and allowed to attach for eight hours prior to drug treatment. For viability testing, cells were treated with 5 μM gefitinib (#076091; Matrix Scientific, Columbia, SC), 10 μM erlotinib (#10483; Cayman Chemical; Ann Arbor, MI), or 10 nM cetuximab (#NBP2-75903; Novus Biologicals; Centennial, CO), with or without BAY 11–7085 (#B3033; ApexBio Technology; Houston, TX) at 2 μM or 3.3 μM for 48 hours. DMSO vehicle controls were included. For all treatments the final DMSO concentration was 1%. After 48 hours cell viability was assessed using the MTS assay (Biovision; Milpitas, CA) as previously described [35 (link)]. Viability was calculated by normalizing each cell line to vehicle treatment alone.